Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group. Sorensen PS, et al. Among authors: petersen t. Lancet. 2003 Oct 11;362(9391):1184-91. doi: 10.1016/S0140-6736(03)14541-2. Lancet. 2003. PMID: 14568740 Clinical Trial.
Antibodies to IFN-beta: the Danish National IFN-beta Project.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group; Danish Interferon-beta Project. Sorensen PS, et al. Among authors: petersen t. Neurology. 2003 Nov 11;61(9 Suppl 5):S27-8. doi: 10.1212/01.wnl.0000092362.44313.b6. Neurology. 2003. PMID: 14610108 Clinical Trial. No abstract available.
[Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
Sørensen S, Koch-Henriksen NJ, Pedersen CR, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E; Dansk Multipel Sklerose Gruppe. Sørensen S, et al. Among authors: petersen t. Ugeskr Laeger. 2004 Oct 4;166(41):3606-9. Ugeskr Laeger. 2004. PMID: 15515467 Danish. No abstract available.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, Heltberg A, Kristensen O, Stenager E, Petersen T, Hansen T; Danish Multiple Sclerosis Group. Koch-Henriksen N, et al. Among authors: petersen t. Neurology. 2006 Apr 11;66(7):1056-60. doi: 10.1212/01.wnl.0000204018.52311.ec. Epub 2006 Mar 1. Neurology. 2006. PMID: 16510769 Clinical Trial.
The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1.
Nexø BA, Christensen T, Frederiksen J, Møller-Larsen A, Oturai AB, Villesen P, Hansen B, Nissen KK, Laska MJ, Petersen TS, Bonnesen S, Hedemand A, Wu T, Wang X, Zhang X, Brudek T, Maric R, Søndergaard HB, Sellebjerg F, Brusgaard K, Kjeldbjerg AL, Rasmussen HB, Nielsen AL, Nyegaard M, Petersen T, Børglum AD, Pedersen FS. Nexø BA, et al. Among authors: petersen ts, petersen t. PLoS One. 2011 Feb 2;6(2):e16652. doi: 10.1371/journal.pone.0016652. PLoS One. 2011. PMID: 21311761 Free PMC article.
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB; SIMCOMBIN study investigators. Sorensen PS, et al. Lancet Neurol. 2011 Aug;10(8):691-701. doi: 10.1016/S1474-4422(11)70144-2. Lancet Neurol. 2011. PMID: 21742556 Clinical Trial.
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry.
Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H; MSBase Study Group. Hughes S, et al. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):305-10. doi: 10.1136/jnnp-2011-301051. Epub 2011 Dec 28. J Neurol Neurosurg Psychiatry. 2012. PMID: 22205675
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
1,408 results